Sonnet to acquire Relief Therapeutics to develop atexakin alfa
Category: #health  By Mateen Dalal  Date: 2019-08-13
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Sonnet to acquire Relief Therapeutics to develop atexakin alfa

Sonnet proposes to pay 7,111,947 common shares and outstanding common stocks to Relief Therapeutics.

Sonnet BioTherapeutics, Inc., a biotechnology company that develops innovative biologic drugs, has recently announced that it has entered into an agreement with Relief Therapeutics Holding SA (RLF). The deal entails the development of atexakin alfa following acquisition of its arm Relief Therapeutics SA via a share exchange transaction.

As per reports, atexakin alfa is a low-dose formulation of IL-6 (interleukin-6), a cytokine with pleiotropic function in various organs and tissues that has successfully cleared Phase I trials. The clinical investigations which were conducted on various settings with more than 700 patients managed to set up a maximum tolerated dose (MTD).

Sources cite that Sonnet will continue atexakin alfa’s (SON-080) development in Chemotherapy Induced Peripheral Neuropathy (CIPN) and could extend to other neuropathies like Diabetic Neuropathy as well.

Speaking on the move, Pankaj Mohan, PhD, Chairman, Sonnet BioTherapeutics, said that after thoroughly studying the clinical and preclinical data, the company feels that atexakin has the potential to be an effective and safe treatment for CIPN, a disease with unmet medical needs.

He said that the company is excited to integrate atexakin to its oncology pipeline, as it possesses the potential to be a commercial blockbuster by treating a patient population that requires undivided medical attention.

Reportedly, the transaction is likely to close at the time when Sonnet would go public, after which, it will take over the development of SON-080 and all its proprietary experimental drugs. Additionally, an international investor has agreed to invest up to $100 million, via a common stock purchase contract, to back Sonnet’s public operations, which is also anticipated to close when Sonnet becomes public.

As per Jay Cross, Chief Financial Officer, Sonnet BioTherapeutics, this agreement offers the company access to capital when needed and the flexibility to follow other avenues of funding. Cross said that the agreement will provide their firms an opportunity to focus on executing their R&D strategy.

Source Credit: https://finance.yahoo.com/news/sonnet-biotherapeutics-announces-acquisition-agreement-114700034.html

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Lufthansa Group to swap old A340 planes with 10 new long-haul jets

Lufthansa Group to swap old A340 planes with 10 new long-haul jets

By Mateen Dalal

The parent company of German airline Deutsche Lufthansa AG, Lufthansa Group, reportedly said it would purchase a total of 10 long-haul aircraft, including 5 Boeing B787-9s and 5 Airbus A350-900s, to replace aging Airbus A340 planes in an effort to mo...

Facebook, Google sign content deals with Australia’s Seven West Media

Facebook, Google sign content deals with Australia’s Seven West Media

By Mateen Dalal

Seven West Media, an Australian newspaper and television firm, has reportedly signed a content deal with Facebook Inc. and Google LLC in the wake of recent landmark laws that have enabled the industry to obtain new revenue sources and adapt to the in...

Microsoft considered reducing Xbox Store fee to revive console gaming

Microsoft considered reducing Xbox Store fee to revive console gaming

By Mateen Dalal

Multinational tech-giant Microsoft was reportedly looking to lower its Xbox store commission fee to a meager 12% from the previous 30%, as per confidential documents submitted in the Epic Games and Apple case. The document from January also contains...